Mantripragada, S. (2002). A lipid based depot (DepoFoam technology) for sustained release drug delivery. Progress in Lipid Research, 41(5), 392-406.
McMillan, D.E., Hardwick, W.C., Li, M., and Owens, S.M. (2002). Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody. Behavioral Pharmacology, 13(5-6), 465-473.
Mets, B., Winger, G., Cabrera, C., Seo, S., Jamdar, S., Yang, G., Zhao, K., Briscoe, R.J., Almonte, R., Woods, J.H., and Landry, D.W. (1998). A catalytic antibody against cocaine prevents cocaine’s reinforcing and toxic effects in rats. Proceedings of the National Academy of Sciences, USA, 95(17), 10176-10181.
Modesto-Lowe, V., and Van Kirk, J. (2002). Clinical uses of naltrexone: A review of the evidence. Experimental and Clinical Psychopharmacology, 10(3), 213-227.
Owens, S.M., and Mayersohn, M. (1986). Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs. Drug Metabolism and Disposition, 14(1), 52-58.
Owens, S.M., Zorbas, M., Lattin, D.L., Gunnell, M., and Polk, M. (1988). Antibodies against arylcyclohexylamines and their similarities in binding specificity with the phencyclidine receptor. Journal of Pharmacology and Experimental Therapeutics, 246(2), 472-478.
Pentel, P.R., and Keyler, D.E. (2004). Vaccination as a treatment for drug abuse: Nicotine, cocaine, phencyclidine. In M.M. Levine (Ed.), New generation vaccines. New York: Marcel Dekker.
Pentel, P.R., Malin, D.H., Ennifar, S., Hieda, Y., Keyler, D.E., Lake, J.R., Milstein, J.R., Basham, L.E., Coy, R.T., Moon, J.W., Naso, R., and Fattom, A. (2000). A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacology, Biochemistry, and Behavior, 65(1), 191-198.
Plessinger, M.A. (1998). Prenatal exposure to amphetamines: Risks and adverse outcomes in pregnancy. Obstetrics and Gynecology Clinics of North America, 25(1), 119-138.
Proksch, J.W., Gentry, W.B., and Owens, S.M. (2000). Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. Journal of Pharmacology and Experimental Therapeutics, 292(3), 831-837.
Putney, S.D., and Burke, P.A. (1998). Improving protein therapeutics with sustained-release formulations. Nature Biotechnology, 16(2), 153-157.
Sanderson, S.D., Cheruku, S.R., Padmanilayam, M.P., Vennerstrom, J.L., Thiele, G.M., Palmatier, M.I., and Bevins, R.A. (2003). Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. International Immunopharmacology, 3(1), 137-146.
Sellers, E.M., Kaplan, H.L., and Tyndale, R.F. (2000). Inhibition of cytochrome P450 2A6 increases nicotine’s oral bioavailability and decreases smoking. Clinical Pharmacology and Therapeutics, 68(1), 35-43.
Shoeman, D., Keyler, D.E., and Pentel, P. (2002). Vaccination of female rats against nicotine reduces nicotine distribution to fetal brain (abstract). Paper presented at the Society for Research on Nicotine and Tobacco Annual Meeting, February, Savannah, GA.
Simister, N.E., and Story, C.M. (1997). Human placental Fc receptors and the transmission of antibodies from mother to fetus. Journal of Reproductive Immunology, 37(1), 1-23.
St. Clair Roberts, J., Dobson, J., Wood, D., and Settles, M. (2002). Safety and immunogenicity of a human nicotine conjugate vaccine (abstract). Paper presented at the College on Problems of Drug Dependence Annual Meeting, June, Quebec City.
Streeton, C., and Whelan, G. (2001). Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: A meta-analysis of randomized controlled trials. Alcohol and Alcoholism, 36(6), 544-552.